Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation
Status:
Completed
Trial end date:
2002-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were
destroyed by chemotherapy used to kill tumor cells. Sometimes the transplanted cells can make
an immune response against normal tissues. Methotrexate and cyclosporine may prevent this
from happening.
PURPOSE: Phase III trial to study the effectiveness of treatment with methotrexate and
cyclosporine after bone marrow transplantation to provide protection against acute
graft-versus-host disease.